Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29227966 | 1.00 | CA2 (0.30) | CA2 | |
| SCHEMBL29041301 | 1.00 | CA2 (0.30) | CA2 | |
| SCHEMBL5690410 | 0.78 | TDP1 (0.33) | — | |
| SCHEMBL367022 | 0.77 | — | — | |
| SCHEMBL367023 | 0.77 | — | — | |
| SCHEMBL2257240 | 0.77 | — | — | |
| SCHEMBL15345921 | 0.74 | UGT2B7 (0.33) | — | |
| SCHEMBL15345922 | 0.74 | UGT2B7 (0.33) | — | |
| SCHEMBL15346017 | 0.71 | UGT2B7 (0.32) | — | |
| SCHEMBL15346018 | 0.71 | UGT2B7 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894431-B | Preparation method of statin drug intermediate | 南京欧信医药技术有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-115894431-A | Preparation method of statin drug intermediate | 南京欧信医药技术有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-109574938-B | Method for synthesizing rosuvastatin sodium | 安徽省庆云医药股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-113651802-B | One-pot preparation method of pitavastatin calcium intermediate | 天地恒一制药股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-109574998-B | Synthetic method of pitavastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-118359621-B | Preparation method of intermediates of Li Siwei and Li Siwei and corresponding intermediates of Li Siwei | 上海陶术生物科技股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-115894431-B | Preparation method of statin drug intermediate | 南京欧信医药技术有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-115894431-B | Preparation method of statin drug intermediate | 南京欧信医药技术有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118359621-A | Preparation method of intermediates of Li Siwei and Li Siwei and corresponding intermediates of Li Siwei | 上海陶术生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118359622-A | Preparation method of Li Siwei intermediate | 上海陶术生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118359623-A | Synthesis method, intermediate and application of forodesine | 上海陶术生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-112409333-B | Phenylpyrrolidine compounds | 武汉人福创新药物研发中心有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20100076206-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2010-03-25 | — | — | US | disclosed |
| EP-2102196-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZaCh System S.p.A. (IT) | 2009-09-23 | — | — | EP | disclosed |
| CN-101541791-A | Process for preparing nebivolol | ZACH SYSTEM SPA (IT) | 2009-09-23 | — | — | CN | disclosed |
| WO-2008064826-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-06-05 | — | — | WO | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| EP-1680509-A1 | METHOD FOR PRODUCING HYDROCARBONS AND OXYGEN-CONTAINING COMPOUNDS, FROM BIOMASS | Swedish Biofuels AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050112739-A1 | Method for producing hydrocarbons and oxygen-containing compounds from biomass | SWEDISH BIOFUELS AB (SE) | 2005-05-26 | — | — | US | disclosed |
| WO-2005040392-A1 | METHOD FOR PRODUCING HYDROCARBONS AND OXYGEN-CONTAINING COMPOUNDS, FROM BIOMASS | SWEDISH BIOFUELS AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076206-A1 | PROCESS FOR PREPARING NEBIVOLOL | ADRB1, ADRB2, ADRA1B | CA2 4180/4885 |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | HTR2C, HTR2A, HTR1A | CA2 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.